STOCK COMMENTS / EPS CHANGESathenahealth ( ATHN) target raised at Jefferies. Shares of ATHN now seen reaching $85, Jefferies said. Recent HMA win validates ability to compete. Hold rating. Baker Hughes ( BHI) numbers raised at UBS. Shares of BHI now seen reaching $65, UBS said. Estimates also increased on solid N. Am results. Buy rating. CME Group ( CME) numbers cut at Citigroup. Shares of CME now seen reaching $58, Citigroup said. Estimates also lowered as volume environment remains challenging. Buy rating. Coach ( COH) numbers lowered at UBS. Shares of COH now seen reaching $63, UBS said. Estimates also lowered on weakening US growth outlook. Neutral rating. Cytec ( CYT) estimates, target cut at Keybanc. Shares of CYT now seen reaching $80, according to Keybanc. Estimates also reduced, given the sale of the coatings resin business. Buy rating. First Horizon ( FHN) numbers reduced at Credit Suisse. FHN estimates were cut through 2014, Credit Suisse said. Company is seeing lower fee income and higher costs. Outperform rating and new $9 price target. General Electric ( GE) estimates lowered at Morgan Stanley through 2014, Morgan Stanley said. Backlog is flattening. Equal-weight rating and $22 price target. Google ( GOOG) estimates raised at Oppenheimer through 2013, Oppenheimer said. Updating model for Motorola Mobility acquisition. Outperform rating. Johnson Controls ( JCI) numbers reduced at Morgan Stanley. JCI estimates were cut through 2014, Morgan Stanley said. Company lacks near-term catalysts. Overweight rating and new $38 price target. Manpower ( MAN) estimates, target cut at BofA/Merrill. Shares of MAN now seen reaching $45, according to Bank of America/Merrill Lynch said. Estimates also reduced, given slower growth in Europe. Outperform rating. Marriott ( MAR) cut from Conviction Buy List at Goldman. RevPAR growth is below the broader industry. MDC ( MDC) added to Conviction Buy List at Goldman. $50 price target. Strong housing recovery appears to be starting. Onyx Pharmaceuticals ( ONXX) numbers increased at Goldman. ONXX estimates were raised through 2015, Goldman Sachs said. Kyprolis is coming to market sooner than expected and should have better pricing. Buy rating and new $85 price target. Philip Morris International ( PM) numbers raised at Jefferies. Shares of PM now seen reaching $92, Jefferies said. Estimates also raised on solid earnings. Hold rating. Suntrust ( STI) estimates, target raised at Credit Suisse. Shares of STI now seen reaching $27, according to Credit Suisse. Estimates also increased, as the company is seeing higher mortgage banking and trading revenue. Outperform rating. Xerox ( XRX) estimates, target reduced at Morgan Stanley. XRX estimates were cut through 2013, given a weaker macro outlook. Neutral rating and new $8 price target. >To submit a news tip, email: firstname.lastname@example.org.
Twitter and become a fan on Facebook.